Skip to content

Author

E. González Barca

2 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Nov 2026

Real-world evidence study of brentuximab vedotin retreatment in patients with cutaneous T-cell lymphoma in Europe.

In advanced cutaneous T-cell lymphoma (CTCL), allogeneic stem cell transplant is the only curative option, but many patients are ineligible and relapse after systemic therapy, requiring retreatment with prior therapies. Brentuximab vedotin (BV), an anti-CD30 monoclonal antibody drug conjugated with monomethyl auristati...

C. Mitteldorf, A. de Masson, M. Beylot-Barry et al. · 0 citations
Open access Sep 2026

Phase 1, open-label, multicenter study of sovleplenib (HMPL-523) in patients with relapsed or refractory lymphoma.

Relapsed or refractory lymphoma carries poor prognosis, with limited options after standard therapies. Spleen tyrosine kinase (SYK) mediates B-cell receptor and aberrant T-cell receptor signaling, promoting survival and proliferation. HMPL-523 (sovleplenib) is a novel, selective oral SYK inhibitor with preclinical acti...

P. Strati, D. Chraniuk, E. González Barca et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.